Corporate
2018.02.22
USPTO granted LT3001 patent
US Patent Granted for Lumosa's New Drug to Treat Acute Ischemic Stroke (Taipei, Taiwan. February 22, 2018) Lumosa Therapeutics (6535.TWO) is pleased to announce that USPTO has issued the US patent (No. US9890193) for the company's new drug candidate, LT3001, which is under development for the treatment of acute ischemic stroke. This is the second patent approval of LT3001 in a major market after the State Intellectual Property Office of China granted LT3001 patent in 2017. Intellectual property of LT3001 is now protected in the two largest pharmaceutical markets in the world, which enhanced the market value of LT3001.
Corporate
2018.01.16
Lumosa licenses CS011, an extended release analgesic injection, to SVP for animal use
Lumosa Therapeutics Licenses Long Acting Injectable Analgesic to Skyline Vet Pharma, Inc. for Use in Companion Animals
Corporate
2017.10.30
Lumosa invited to 2017 STAIR X
Lumosa was invited to the tenth Stroke Treatment Academic Industry Roundtable (STAIR X) held on October 23-24 in Washington D.C., USA, where top scientists and specialists gather to publish the latest research on cerebral stroke. Applications of neuroprotection agents on acute ischemic stroke were discussed during the STAIR conference. Neuroprotectants may protect the brain from ischemia and can be combined with thrombectomy to extend the "Golden Hour" and enhance treatment effect. Lumosa's LT3001 possess thrombolytic and neuroprotective functions and is currently under Phase 1 trial in the US.
Corporate
2017.09.11
Media exposure by GlobalData
Media exposure by GlobalData
Corporate
2017.08.28
Lumosa partners with Camargo for LT1001
Lumosa Therapeutics Partners with Camargo Pharmaceutical Services in the Development of Naldebain(R) in the US
Corporate
2017.06.20
USFDA approved the phase 1 trial for LT3001
Lumosa Therapeutics Co., Ltd., (TPEx: 6535, hereinafter 'Lumosa') is pleased to announce that its lead drug candidate for acute ischemic stroke, LT3001, has received approval from the US FDA to begin Phase I clinical trials. The first clinical trial is a double-blinded dose escalating study in healthy volunteers and expected to be completed in the first half of 2018.